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Purpose: Intrinsic and acquired resistance of tumor cells to 
therapy originates from multiple avenues. One avenue 
includes extracellular matrix (ECM) and proteins that 
facilitate cell interaction with ECM. These focal adhesion 
(FA) proteins coalesce at specific membrane sites as large 
multiprotein complexes functioning as signaling hubs and 
structural nexus. Molecular targeting of various FA proteins 
has shown promising preclinical data. Even more interesting 
are rather recent findings about activation of prosurvival 
bypass signaling under specific inhibition of integrins and 
their dependence on ECM stiffness. 
Materials/methods: Different tumor models were 
investigated such as head and neck, pancreatic ductal 
carcinoma, glioblastoma. We performed a systematic 
targeting of FA proteins using siRNA or antibodies where 
applicable. In-vitro and in-vivo survival assays and a variety 
of mechanistic studies were conducted. 
Results: To date, integrins turned out as most promising 
druggable candidates. Most interesting, molecular targeting 
generally showed to prominently induce unfavorable 
prosurvival signaling. Multitargeting strategies were 
successful to abrogate this bypass signaling and optimize 
radiochemosensitization. 
Conclusions: Integrins and other FA proteins are promising 
cancer targets. Identification of underlying mechanisms is 
still the needle eye. From our data, multitargeting 
approaches on top of conventional radiochemotherapy look 
beneficial as specific tumor cell functions can be inhibited. 
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Purpose: In-Beam PET is a well-established method for dose 
monitoring in hadrontherapy, but its effectiveness is still 
limited by the accelerator duty cycle [1]. CABOTO [2, 3], 
CArbon BOoster for Therapy in Oncology, is an innovative 
development project of an efficient high-frequency linac for 
hadrontherapy that can accelerate 12C ions and H2 molecules 
up to 430 MeV/u, bunched in pulses of the order of 2-5 µs 
with a repetition rate of 360 Hz. 
Thanks to its low duty cycle (less than 0.1%), CABOTO allows 
the γ-pair acquisition with PET during 99.9% of the treatment 
time. The main goal of this research is to describe how the 
CABOTO time-structure influences the in-beam PET images, 
reconstructed by acquiring the γ-coincidences during the 
irradiation time as well as in a period following it. 
Methods and Materials: The study has been carried out 
performing several simulations with the FLUKA Monte Carlo 
code [4, 5] together with MATLAB routines written to take 
into account analytically the CABOTO time structure. 
In a first set of simulations, the β+ emitter isotopes, 
produced by the interaction of a pencil beam (protons and 
12C-ions) with a water phantom, are identified. Due to the 
special time structure, the PET detector is sensitive also to 
γ-pair produced in the β+-decays of isotopes having half-lives 
(T1/2) in the ms range; the most relevant ones are 13O 
(T1/2=8.6 ms), 12N (T1/2=11 ms), 9C (T1/2=126.5 ms), 8B 
(T1/2=770 ms). Considering the CABOTO time structure and 
the acquisition time window as defined before, the β+ 
activity versus time has been extrapolated for all β+ emitters. 
A second set of simulations including a PET detector has been 
carried out, using a modified version of the routines 
originally developed in Fluka for conventional PET [6]. Arrival 
times of gamma pair coincidences on the PET detector have 
been scored and analysed in order to verify their 
correspondence to the beam irradiation profile. The history 
of each coincidence has been traced in order to identify the 
parent isotope, which helps to discriminate and evaluate the 
true signal versus the background noise. Based on this 
information, the PET images could be reconstructed from the 
true coincidences from both the online and offline signal, and 
quantify the differences. 
Results & Conclusions: This work describes the results 
obtained in the study of the influence of CABOTO time 
structure on the PET scanner reconstruction. The β+ activity 
collected during the irradiation with a single pencil beam has 
been computed together with the estimated background 
during the irradiation. The effect of the very short half-life 
β+ emitters, which produce positrons of longer ranges, has 
been studied. Preliminary results obtained in a simulation on 
a real patient case, with all the beam spots delivered with 
the correct time structure, are also presented. 
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The number of facilities that offer tumor treatment with 
particle therapy has been increasing substantially over the 
past decades. The dose distribution deposited by ions, and 
for the heaviest, their higher biological effectiveness, make 
them more interesting to destroy localized tumors while 
sparing healthy tissues. Such an effectiveness is quantified 
through the RBE (relative biological effectiveness), which is a 
complex function of multiple parameters like cell line, cell 
cycle stage, radiation quality and irradiation conditions. 
Therefore, determining the value of RBE for every scenario is 
a challenging task that requires modeling to comply with the 
demands of a clinical environment. 
Several solutions have already been developed and a few are 
currently used in treatment planning [1-4]. Nevertheless, 
despite the progress these models have allowed, they present 
some shortcomings [5-7] that may limit their improvement. 
We present thereby a new approach that gathers some 
principles of the existing ones and addresses some of their 
weaknesses. The innovative features of NanoxTM are that it is 
fully based on statistical physics, taking in particular into 
account the fluctuations in energy deposition at multiple 
scales, and that it introduces the concept of a chemical dose. 
The latter is chosen as a parameter defined at the cell scale 
to represent the induction of cell death by “non-local” 
events as the accumulation of cellular oxidative stress or sub-
lethal lesions induced by the produced radical species. Such 
“non-local” events are complementary to the so-called 
“local” events, which take place at a very localized 
(nanometric) scale. The “local” events are considered as 
lethal since a single event can cause cell death. 
The cell survival predicted by NanoxTM for V79 cell line was 
compared with experimental results for photons, protons and 
carbon ions, and even others like neon and argon ions. A good 
agreement was found in all cases. In particular, the model is 
able to describe the effectiveness of ions, including the 
overkill effect at higher LET values. Moreover, NanoxTM can 
reproduce the typical shoulder in cell survival curves. This 
was possible due to the introduction of the “non-local” 
events, through the chemical dose, which varies with LET. It 
is worthwhile to note that such results were obtained through 
the adjustment of a reduced number of free parameters. 
The first results of NanoxTM, obtained for V79 cell line, give 
us confidence that this model has potential for application in 
a clinical scenario in the context of particle therapy. 
Although it requires the tuning of only a few free 
parameters, NanoxTM is based on solid principles and a 
thorough mathematical implementation, which renders this 
approach simple but reliable for application in clinical 
practice. 
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Purpose: The advent of personalized medicine in 
radiotherapy (RT) is accompanied by the need for accurate 
outcome prediction. The current state of predictions made 
by physicians for patient survival and toxicity after lung 
radiotherapy is comparable to flipping a coin (Oberije et 
al.,Radiother. Oncol. 2014). In order to assess the value of 
expert knowledge in prediction modelling (rather than 
directly predicting outcomes), expert-based and data-driven 
prediction models were built and compared. Models for two 
endpoints were created: 2-year survival in NSCLC non-surgery 
patients and severe dyspnea (CTCAE dyspnea scores ≥ 2) after 
RT. 
Materials/methods: Data from lung cancer patients (994 for 
dyspnea, 452 for 2-year survival) treated in clinical routine 
were collected. 10 experts (4 experts participated for both 
endpoints) selected causal links between patient, disease, 
treatment, and dose-related variables (19 for dyspnea, 17 for 
2-year survival) and the two outcomes. The selected links 
were used to construct Bayesian Networks (BN) for a 
comparison with BNs based on a data-driven algorithm. These 
models were then learned on 80% and validated on 20% of the 
patient data. Discrimination in the validation data sets is 
assessed by the Area under the Curve (AUC). 
